A large part of the funding will go to the research and development of CIN-107 as it has shown the potential to treat primary aldosteronism and treatment-resistant hypertension.
The NIH revealed that bumetanide, a drug typically used as a diuretic, maybe a potential treatment for those genetically at risk for Alzheimer’s. Know more about it here.
This followed a report that found that some trustees had, perhaps, taken advantage of this close connection with startups and research programs for their financial gain.
Its Phase III MODIFY study had hoped to find a positive effect of its oral substrate reduction therapy lucerastat on adult patients who have been diagnosed with Fabry disease.
Roche’s candidate drug for Alzheimer’s treatment received breakthrough therapy designation which has increased its chance of getting full FDA approval.
Litigator Block & Leviton is launching an investigation into Ginkgo Bioworks after short seller Scorpion Capital released a report alleging that Ginkgo is running a fraudulent operation.
The deal, which includes an upfront payment of $1.75 billion, enables Boston Scientific to expand its electrophysiology and structural heart product portfolio.
The company announced that they are reducing its employee headcount and ceasing some of its research programs to focus on its geographic atrophy (GA) trial.
The DOL’s Office of Federal Contract Compliance Programs found that AstraZeneca paid a much lower base salary than similar employees to 23 Hispanic female staff and 295 female employees.
